| Literature DB >> 18385815 |
M Muddassar1, F A Pasha, H W Chung, K H Yoo, C H Oh, S J Cho.
Abstract
Research by other investigators has established that insulin-like growth factor-1 receptor (IGF-1R) is a key oncological target, and that derivatives of 1, 3-disubstituted-imidazo[1,5-alpha] pyrazine are potent IGF-1R inhibitors. In this paper, we report on our three-dimensional quantitative structure activity relationship (3D-QSAR) studies for this series of compounds. We validated the 3D-QSAR models by the comparison of two major alignment schemes, namely, ligand-based (LB) and receptor-guided (RG) alignment schemes. The latter scheme yielded better 3D-QSAR models for both comparative molecular field analysis (CoMFA) (q(2) = 0.35, r(2) = 0.95) and comparative molecular similarity indices analysis (CoMSIA) (q(2) = 0.51, r(2) = 0.86). We submit that this might arise from the more accurate inhibitor alignment that results from using the structural information of the active site. We conclude that the receptor-guided 3D-QSAR may be helpful to design more potent IGF-1R inhibitors, as well as to understand their binding affinity with the receptor.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18385815 PMCID: PMC2276912 DOI: 10.1155/2008/837653
Source DB: PubMed Journal: J Biomed Biotechnol ISSN: 1110-7243
The structures and observed IGF inhibitory activities [15].
| No. | Structure | R | IC50 (M) | pIC50 |
|---|---|---|---|---|
| 1 | A | 4-OBn | 1.97 × 10−6 | 5.706 |
| 2 | A | 3-OH | 0.518 × 10−6 | 6.286 |
| 3 | A | 3-OBn–4-OMe | 1.35 × 10−6 | 5.870 |
| 4 | A | 3-OBn–4-OH | 3.31 × 10−6 | 5.480 |
| 5* | B | Cyclopentyl | 3.5 × 10−6 | 5.456 |
| 6 | B | Cyclohexyl | 1.05 × 10−6 | 5.979 |
| 7* | B | –CH2–cyclopropyl | 2.27 × 10−6 | 5.644 |
| 8* | B | –CH2–cyclohexyl | 1.11 × 10−6 | 5.955 |
| 9 | B | –CH2CH2OMe | 6.28 × 10−6 | 5.202 |
| 10 | B | –CH2–2-pyridyl | 1.09 × 10−6 | 5.963 |
| 11 | C | H | 0.606 × 10−6 | 6.218 |
| 12 | C | 2-F | 0.224 × 10−6 | 6.650 |
| 13 | C | 3-F | 0.51 × 10−6 | 6.292 |
| 14 | C | 4-F | 1.23 × 10−6 | 5.910 |
| 15 | C | 2-Cl | 0.343 × 10−6 | 6.465 |
| 16 | C | 3-Cl | 2.12 × 10−6 | 5.674 |
| 17* | C | 4-Cl | 0.980 × 10−6 | 6.009 |
| 18 | C | 2-OCF2H | 3.28 × 10−6 | 5.484 |
| 19 | C | 3-OCF2H | 5.78 × 10−6 | 5.238 |
| 20 | C | 4-OCF2H | 2.82 × 10−6 | 5.550 |
| 21 | C | 2,3-Difluoro | 0.898 × 10−6 | 6.047 |
| 22 | C | 3,4-Difluoro | 4.48 × 10−6 | 5.349 |
| 23* | C | 2,5-Difluoro | 0.329 × 10−6 | 6.483 |
| 24 | C | 2,6-Difluoro | 0.215 × 10−6 | 6.668 |
| 25 | C | 3,5-Difluoro | 1.35 × 10−6 | 5.870 |
| 26 | C | 2,6-Dichloro | 1.67 × 10−6 | 5.777 |
| 27 | C | 2-Cl,6-F | 0.248 × 10−6 | 6.606 |
| 28 | D | Cyclopentyl | 1.05 × 10−6 | 5.979 |
| 29 | D | Cyclohexyl | 3.51 × 10−6 | 5.455 |
| 30 | D | Cycloheptyl | 3.79 × 10−6 | 5.421 |
| 31* | D | Phenyl | 1.68 × 10−6 | 5.775 |
| 32 | E | trans-NH2 | 0.221 × 10−6 | 6.656 |
| 33 | E | cis-NH2 | 0.775 × 10−6 | 6.111 |
| 34* | E | trans-NHMe | 0.105 × 10−6 | 6.979 |
| 35 | E | trans-Pyrrolodinyl | 1.82 × 10−6 | 5.740 |
| 36* | E | trans-Piperidinyl | 3.40 × 10−6 | 5.469 |
| 37 | E | trans-NHPh | 1.30 × 10−6 | 5.886 |
| 38 | E | trans-NHBn | 1.39 × 10−6 | 5.857 |
| 39 | F | trans-NH2 | 0.119 × 10−6 | 6.924 |
| 40 | F | cis-NH2 | 0.228 × 10−6 | 6.642 |
| 41 | F | trans-N(Et)2 | 0.115 × 10−6 | 6.939 |
| 42 | F | trans-Azetidinyl | 0.081 × 10−6 | 7.092 |
| 43 | F | trans-Pyrrolidinyl | 0.103 × 10−6 | 6.987 |
| 44* | F | trans-Morpholino | 0.091 × 10−6 | 7.041 |
| 45* | G | trans-Pyrrolidinyl | 0.116 × 10−6 | 6.936 |
| 46 | G | cis-Pyrrolidinyl | 0.089 × 10−6 | 7.051 |
| 47 | G | cis-NH2 | 0.060 × 10−6 | 7.222 |
| 48 | G | cis-NMe2 | 0.166 × 10−6 | 6.780 |
| 49* | G | cis-Piperidinyl | 0.237 × 10−6 | 6.625 |
| 50 | G | cis-Morpholino | 0.148 × 10−6 | 6.830 |
| 51 | G | cis-NH-iPr | 0.220 × 10−6 | 6.658 |
| 52 | G | cis-N(Me)-Piperizinyl | 0.265 × 10−6 | 6.577 |
| 53 | H | trans-NH2 | 0.526 × 10−6 | 6.279 |
| 54 | H | cis-NH2 | 0.554 × 10−6 | 6.256 |
* Compounds used in the test set.
Statistical summary of different PLS analysis. (GS: geometrical scheme; SE: standard error of estimate; n.: number of components; F: Fischer's F value for test of significance; r2bs: coefficient of determination after 100 bootstrapping runs; SD: standard deviation; Field contribution: (S) steric field, (E) electrostatic field, (H) hydrophobic field, (D) H-bond donor field, and (A) H-bond acceptor field.).
| Analysis | GS | Field | n. | SE | SD | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| CoMFA | LB | S | 0.52 | 4 | 0.84 | 50.12 | 0.23 | — | — | — |
| CoMFA | LB | E | 0.38 | 3 | 0.73 | 34.7 | 0.30 | — | — | — |
| CoMFA | LB | 0.49S/0.51E | 0.52 | 4 | 0.88 | 70 | 0.20 | 0.91 | 0.1 | 0.67 |
| CoMFA | RG | S | 0.38 | 4 | 0.72 | 24.5 | 0.31 | — | — | — |
| CoMFA | RG | E | 0.42 | 7 | 0.86 | 33.12 | 0.22 | — | — | — |
| CoMFA | RG | 0.45/0.55 | 0.53 | 6 | 0.95 | 113.6 | 0.13 | 0.97 | 0.00 | 0.67 |
| CoMSIA | LB | S | 0.27 | 3 | — | — | — | — | — | — |
| CoMSIA | LB | E | 0.36 | 1 | — | — | — | — | — | — |
| CoMSIA | LB | H | 0.32 | 4 | — | — | — | — | — | — |
| CoMSIA | LB | D | 0.00 | 1 | — | — | — | — | — | — |
| CoMSIA | LB | A | 0.33 | 2 | — | — | — | — | — | — |
| CoMSIA | LB | E/S | 0.37 | 2 | — | — | — | — | — | — |
| CoMSIA | LB | 0.60E/0.40A | 0.41 | 2 | — | — | — | — | — | — |
| CoMSIA | LB | 0.73E/0.27D | 0.41 | 3 | — | — | — | — | — | — |
| CoMSIA | LB | 0.51E/.49H | 0.39 | 2 | — | — | — | — | — | — |
| CoMSIA | LB | 0.41E/0.27S/0.31A | 0.42 | 4 | 0.80 | 39.2 | 0.26 | 0.85 | 0.04 | 0.57 |
| CoMSIA | LB | E/A/D | 0.41 | 2 | — | — | — | — | — | — |
| CoMSIA | RG | S | 0.37 | 1 | — | — | — | — | — | — |
| CoMSIA | RG | E | 0.46 | 4 | — | — | — | — | — | — |
| CoMSIA | RG | H | 0.35 | 3 | — | — | — | — | — | — |
| CoMSIA | RG | D | 0.15 | 5 | — | — | — | — | — | — |
| CoMSIA | RG | A | 0.39 | 3 | — | — | — | — | — | — |
| CoMSIA | RG | 0.71E/0.29S | 0.46 | 5 | — | — | — | — | — | — |
| CoMSIA | RG | 0.66E/0.34A | 0.52 | 5 | 0.85 | 41.2 | 0.23 | 0.89 | 0.04 | 0.57 |
| CoMSIA | RG | E/D | 0.48 | 6 | — | — | — | — | — | — |
| CoMSIA | RG | 0.57E/0.43H | 0.48 | 5 | — | — | — | — | — | — |
| CoMSIA | RG | 0.54E/0.21S/0.25A | 0.51 | 5 | 0.86 | 45.4 | 0.22 | 0.9 | 0.03 | 0.64 |
| CoMSIA | RG | E/A/D | 0.47 | 6 | — | — | — | — | — | — |
Statistics of different PLS analysis after region focusing. (GS: geometrical scheme; SE: standard error of estimate; n.: number of components; F: Fischer’s F value for test of significance; r2bs: coefficient of determination after 100 bootstrapping runs; SD: standard deviation; Field contribution: (S) steric field, (E) electrostatic field, (H) hydrophobic field, (D) H-bond donor field, and (A) H-bond acceptor field.).
| Analysis | GS | Field | Grid spacing | n. | SE | SD | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CoMFA | LB | S | 0.5 Å | 0.59 | 5 | 0.84 | 40.41 | 0.234 | 0.89 | 0.11 | 0.65 |
| CoMFA | LB | E | 0.5 Å | 0.13 | 2 | — | — | — | — | — | — |
| CoMFA | LB | 0.57S/0.43E | 0.5 Å | 0.56 | 4 | 0.84 | 49.62 | 0.235 | 076 | 0.13 | 0.68 |
| CoMFA | LB | S | 1.5 Å | 0.25 | 1 | 0.36 | 23.40 | 0.450 | — | — | — |
| CoMFA | LB | E | 1.5 Å | −0.03 | 1 | — | — | — | — | — | — |
| CoMFA | LB | 0.35S/0.65E | 1.5 Å | 0.38 | 2 | 0.51 | 21.20 | 0.40 | — | — | — |
| CoMFA | RG | S | 0.5 Å | 0.41 | 4 | 0.71 | 23.47 | 0.315 | — | — | — |
| CoMFA | RG | E | 0.5 Å | 0.42 | 7 | 0.87 | 33.11 | 0.220 | — | — | — |
| CoMFA | RG | 0.47S/0.53E | 0.5 Å | 0.55 | 6 | 0.94 | 97.78 | 0.145 | 0.96 | 0.02 | 0.67 |
| CoMFA | RG | S | 1.5 Å | 0.44 | 4 | 0.65 | 17.93 | 0.345 | — | — | — |
| CoMFA | RG | E | 1.5 Å | 0.11 | 4 | 0.26 | 3.32 | 0.505 | — | — | — |
| CoMFA | RG | 0.45S/0.50E | 1.5 Å | 0.29 | 3 | 0.60 | 18.99 | 0.370 | — | — | — |
Experimental and predicted activities with their residuals by CoMFA and CoMSIA analyses of the training set.
| n. | CoMFA | CoMSIA | |||
|---|---|---|---|---|---|
| Experimental | Predicted | Predicted | |||
| pIC50 | pIC50 | Residual | pIC50 | Residual | |
| 1 | 5.706 | 5.553 | 0.153 | 5.646 | 0.060 |
| 2 | 6.286 | 6.296 | −0.010 | 6.172 | 0.114 |
| 3 | 5.870 | 5.948 | −0.078 | 5.781 | 0.089 |
| 4 | 5.480 | 5.888 | −0.408 | 5.814 | −0.334 |
| 6 | 5.979 | 5.365 | 0.614 | 5.421 | 0.558 |
| 9 | 5.202 | 5.275 | −0.073 | 5.074 | 0.128 |
| 10 | 5.963 | 6.200 | −0.237 | 6.199 | −0.236 |
| 11 | 6.218 | 6.191 | 0.027 | 6.135 | 0.083 |
| 12 | 6.650 | 6.276 | 0.374 | 6.330 | 0.320 |
| 13 | 6.292 | 6.065 | 0.227 | 5.849 | 0.443 |
| 14 | 5.910 | 5.870 | 0.040 | 5.842 | 0.068 |
| 15 | 6.465 | 6.487 | −0.022 | 6.363 | 0.102 |
| 16 | 5.674 | 5.927 | −0.253 | 5.787 | −0.113 |
| 18 | 5.484 | 5.473 | 0.011 | 5.589 | −0.105 |
| 19 | 5.238 | 5.102 | 0.136 | 5.579 | −0.341 |
| 20 | 5.550 | 5.615 | −0.065 | 5.625 | −0.075 |
| 21 | 6.047 | 6.015 | 0.032 | 6.226 | −0.179 |
| 22 | 5.349 | 5.544 | −0.195 | 5.754 | −0.405 |
| 24 | 6.668 | 6.571 | 0.097 | 6.474 | 0.194 |
| 25 | 5.870 | 6.034 | −0.164 | 5.832 | 0.038 |
| 26 | 5.777 | 5.929 | −0.152 | 6.416 | −0.639 |
| 27 | 6.606 | 6.586 | 0.02 | 6.498 | 0.108 |
| 28 | 5.979 | 5.981 | −0.002 | 5.676 | 0.303 |
| 29 | 5.455 | 5.471 | −0.016 | 5.562 | −0.107 |
| 30 | 5.421 | 5.473 | −0.052 | 5.604 | −0.183 |
| 32 | 6.656 | 6.366 | 0.290 | 6.297 | 0.359 |
| 33 | 6.111 | 6.366 | −0.255 | 6.297 | −0.186 |
| 35 | 5.740 | 5.706 | 0.034 | 6.068 | −0.328 |
| 37 | 5.886 | 5.934 | −0.048 | 5.864 | 0.022 |
| 38 | 5.857 | 5.828 | 0.029 | 5.763 | 0.094 |
| 39 | 6.924 | 6.826 | 0.098 | 6.785 | 0.139 |
| 40 | 6.642 | 6.826 | −0.184 | 6.785 | −0.143 |
| 41 | 6.939 | 7.009 | −0.070 | 6.951 | −0.012 |
| 42 | 7.092 | 7.032 | 0.060 | 6.916 | 0.176 |
| 43 | 6.987 | 7.012 | −0.025 | 7.008 | −0.021 |
| 46 | 7.051 | 6.950 | 0.101 | 7.130 | −0.079 |
| 47 | 7.222 | 7.325 | −0.103 | 7.126 | 0.096 |
| 48 | 6.780 | 6.763 | 0.017 | 6.881 | −0.101 |
| 50 | 6.830 | 6.776 | 0.054 | 6.842 | −0.012 |
| 51 | 6.658 | 6.648 | 0.010 | 6.806 | −0.148 |
| 52 | 6.577 | 6.547 | 0.030 | 6.429 | 0.148 |
| 53 | 6.279 | 6.328 | −0.049 | 6.298 | −0.019 |
| 54 | 6.256 | 6.328 | −0.072 | 6.298 | −0.042 |
Experimental and predicted activities with their residuals by CoMFA and CoMSIA analyses of the test set.
| n. | CoMFA | CoMSIA | |||
|---|---|---|---|---|---|
| Experimental | Predicted | Predicted | |||
| pIC50 | pIC50 | Residual | pIC50 | Residual | |
| 5 | 5.456 | 5.404 | 0.052 | 5.536 | −0.080 |
| 7 | 5.644 | 5.779 | −0.135 | 5.811 | −0.167 |
| 8 | 5.955 | 6.015 | −0.060 | 5.787 | 0.168 |
| 17 | 6.009 | 5.966 | 0.043 | 5.819 | 0.190 |
| 23 | 6.483 | 6.274 | 0.209 | 6.304 | 0.179 |
| 31 | 5.775 | 5.703 | 0.072 | 5.728 | 0.047 |
| 34 | 6.979 | 6.269 | 0.710 | 6.205 | 0.774 |
| 36 | 5.469 | 5.696 | −0.227 | 5.924 | −0.455 |
| 44 | 7.041 | 7.080 | −0.039 | 7.227 | −0.186 |
| 45 | 6.936 | 6.950 | −0.014 | 7.130 | −0.194 |
| 49 | 6.625 | 6.902 | −0.277 | 6.834 | −0.209 |
Figure 1Comparison of minimum energy (yellow) and docking based (red) conformers.
Figure 2CoMFA electrostatic maps with the most (red) and least (orange) active compound within the active site.
Figure 3CoMFA steric maps with the most (red) and least (orange) active compound within the active site.
Figure 4CoMSIA electrostatic maps with the most (red) and least (orange) active compound within the active site.
Figure 5CoMSIA steric maps with the most (red) and least (orange) active compound within the active site.
Figure 6CoMSIA H-bond acceptor map with the most (red) and least (orange) active compound within the active site.